NEW YORK, Jan. 7, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company’s Board of Directors. “On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant…

Source

Previous articleMydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
Next articleMydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds